Regulation and Effects of FGF23 in Chronic Kidney Disease
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Chronic kidney disease (CKD) is a global health epidemic that accelerates cardiovascular disease, increases risk of infection, and causes anemia and bone disease, among other complications that collectively increase risk of premature death. Alterations in calcium and phosphate homeostasis have long been considered nontraditional risk factors for many of the most morbid outcomes of CKD. The discovery of fibroblast growth factor 23 (FGF23), which revolutionized the diagnosis and treatment of rare hereditary disorders of FGF23 excess that cause hypophosphatemic rickets, has also driven major paradigm shifts in our understanding of the pathophysiology and downstream end-organ complications of disordered mineral metabolism in CKD. As research of FGF23 in CKD has rapidly advanced, major new questions about its regulation and effects continuously emerge. These are promoting exciting innovations in laboratory, patient-oriented, and epidemiological research and stimulating clinical trials of new therapies and repurposing of existing ones to target FGF23.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response
Liu, P. T., Stenger, S., Li, H., Wenzel, L., Tan, B. H., Krutzik, S. R., Ochoa, M. T., Schauber, J., Wu, K., Meinken, C., et al. (2006) · Science · doi:10.1126/science.1123933 · Cited by 3,924
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
Self-citationSuppression of Aging in Mice by the Hormone Klotho
Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., McGuinness, O. P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., et al. (2005) · Science · doi:10.1126/science.1112766 · Cited by 1,935
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Bergwitz, C., & Jüppner, H. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.111339 · Cited by 741 · cited 1×
“The main effects of 1,25-dihydroxyvitamin D on mineral homeostasis include (a) augmenting dietary calcium absorption, which is mediated primarily by vitamin D–dependent active transport; (b) augmenting dietary phosphate absorption, although the majority of phosphate is passively absorbed between enterocytes via parace…”
BackgroundHu, M. C., Shiizaki, K., Kuro-o, M., & Moe, O. W. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183727 · Cited by 587
Ferrari, S. L., Bonjour, J.-P., & Rizzoli, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1039 · Cited by 518 · cited 3×
“Serum phosphate is maintained within a narrow range despite day-to-day dietary fluctuations because FGF23 levels rise and fall in parallel to the amount of dietary phosphate intake (Figure 1) (20).”
BackgroundInfluentialAcute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men
Nishida, Y., Taketani, Y., Yamanaka-Okumura, H., Imamura, F., Taniguchi, A., Sato, T., Shuto, E., Nashiki, K., Arai, H., Yamamoto, H., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5002000 · Cited by 243
Cited by
Lim, Y. J., Sidor, N. A., Tonial, N. C., Che, A., & Urquhart, B. L. (2021) · Toxins · doi:10.3390/toxins13020142 · Cited by 373
Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad083 · Cited by 363
Küng, C. J., Haykir, B., Schnitzbauer, U., Egli-Spichtig, D., Hernando, N., & Wagner, C. A. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00250.2021 · Cited by 38
Gaweda, A. E., McBride, D. E., Lederer, E. D., & Brier, M. E. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00159.2020 · Cited by 13
Egli-Spichtig, D., Hamid, A. K., Arroyo, E. M. P., Ketteler, M., Wiecek, A., Rosenkranz, A. R., Pasch, A., Lorenz, H., Hellmann, B., Karus, M., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad040 · Cited by 9
“There is an ongoing debate about the suitability of including plasma FGF23 as marker of kidney function, kidney disease, cardiovascular disease risk or exposure to phosphate [14, 15].”
Background
Metadata
- Authors
- Musgrove, J., & Wolf, M.
- Venue
- Annual Review of Physiology
- Publisher
- Annual Reviews
- Published
- 2020-02-10
- Volume
- 82
- Issue
- 1
- Pages
- 365-390
- ISSN
- 0066-4278 (ISSN-L)
- 1545-1585
- OpenAlex
- W2991164353
- Cited by
- 127
- References
- 11
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulation and Effects of FGF23 in Chronic Kidney Disease. https://app.cochat.ai/papers/10.1146/annurev-physiol-021119-034650
- The paper
- Musgrove, J., & Wolf, M. (2020). Regulation and Effects of FGF23 in Chronic Kidney Disease. Annual Review of Physiology. https://doi.org/10.1146/annurev-physiol-021119-034650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.